Lung cancer remains the leading cause of cancer death in the United States, claiming nearly 160,000 lives annually. New treatments and therapeutic approaches -- including new combinations of conventional therapies as well as novel targeted agents -- are enabling lung cancer patients to live longer than ever before. Yet most people with lung cancer eventually succumb to the disease, highlighting the need for continued investigations to decipher its molecular basis and to identify new therapeutic targets.
Investigators in the Perlmutter Cancer Center's Thoracic Oncology Program are doing just that: delineating the pathways of lung carcinogenesis, pioneering the exploration of biomarkers to raise the chance of detecting the disease in its earliest stages, and leading clinical trials of new treatments for patients with all stages of lung cancer.
Our basic science and clinical investigators collaborate as a team, talking on a regular basis about their respective avenues of inquiry and clarifying new areas of study. Our program is the machine that drives the discovery and validation of novel biomarker and therapeutic target molecules.